Navigation Links
GeoVax Awarded $3.6 Million Grant by U.S. Government for its HIV/AIDS Vaccine Program

ATLANTA, Aug. 16, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

This grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. Government.  Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award.

This most recent annual award represents the fifth year's award, bringing the aggregate award to date to $19.6 million.  GeoVax will utilize this funding to further production of its GM-CSF adjuvanted vaccine for planned human clinical trials.

"This award will allow us to maintain momentum on the successful development of our GM-CSF adjuvanted vaccine," said Harriet Robinson, Ph.D., Chief Scientific Officer of GeoVax and Program Director for the Award. "Depending on FDA submission schedules, we anticipate beginning a Phase 1 clinical trial within the next six months.  The exciting thing about using the GM-CSF adjuvant is that it significantly increases prevention of infection.  Without the adjuvant, our vaccine has been demonstrated to successfully control infection, but prevention of infection is the ultimate goal.  There is widespread enthusiasm and desire for a vaccine that provides the promise for prevention of infection."

"We just had our annual External Advisory Board Meeting for our GM-CSF adjuvant project," said Robert McNally, Ph.D., President & CEO of GeoVax.  "It was very productive with the outside experts being highly enthusiastic about the GM-CSF adjuvanted vaccine and very complimentary of the progress GeoVax has made."

About GeoVax

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and involves 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

The Investor Relations Group
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
2. Article by GeoVax Labs CSO Featured in The Scientist
3. GeoVax Labs Announces Availability of 2010 Annual Report and Presidents Letter to Stockholders
4. GeoVax Labs, Inc. Announces First Quarter Financial Results
5. GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
6. GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony
7. GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
8. GeoVax Labs, Inc. Reports Data on Prototype Adjuvant - Supplemented HIV Vaccine Tested in Preclinical Animal Studies
9. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
10. GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
11. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):